Study identification

PURI

https://redirect.ema.europa.eu/resource/39377

EU PAS number

EUPAS39376

Study ID

39377

Official title and acronym

Retrospective non-interventional chart review study of the clinical outcomes of guselkumab in the treatment of Finnish patients with plaque psoriasis (FINGUS)

DARWIN EU® study

No

Study countries

Finland

Study description

The study is an observational, retrospective, non-interventional patient chart review study, whose population is Finnish adult patients with confirmed diagnosis of plaque psoriasis (PSO) who have been initiated with guselkumab treatment between 1st December 2017 and 1st december 2019. The primary objective of the study is to investigate the real-life clinical outcomes, and drug survival of gusekumab treatment. The secondary objectives are to characterize the patients who initiated guselkumab treatment during the study timeline, to assess the dosing interval of guselkumab during the induction and maintenance phase of the treatment, to assess the reasons for discontinuation of guselkumab, and to estimate the patients' quality of life through DLQI, if available.

Study status

Finalised
Research institutions and networks

Institutions

Tampere University Hospital
Finland
First published:
01/02/2024
InstitutionEducational InstitutionHospital/Clinic/Other health care facility
Tampere university hospital Tampere Finland, Vaasa central hospital Vaasa Finland, Kuopio university hospital Kuopio Finland, Lohja hospital (HUS) Lohja Finland,
Mikkeli central hospital Mikkeli Finland, Turku university central hospital Turku Finland, Ahvenanmaa central hospital Ahvenanmaa Finland, Helsinki university hospital Helsinki Finland, Central Finland central hospital Jyväskylä Finland, Oulu university hospital Oulu Finland, Savonlinna central hospital Savonlinna Finland,
Kanta-Häme central hospital Hämeenlinna Finland, Päijät-Häme central hospital Lahti Finland, Kainuu central hospital Kajaani Finland, Länsi-Pohja hospital Kemi Finland

Contact details

Rafael Pasternack

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Data analysis start date

Actual:

Date of final study report

Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Janssen-Cilag Oy
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable